Oncology Business Management | Specialty

Value-Based Purchasing: How Physicians Will Be Compensated in the Future

May 10th 2013

An interview with Frank G. Opelka, MD, exploring some of the health policy initiatives that will impact how physicians will be compensated in the future.

Integrating New Therapies Into the Prostate Cancer Continuum

May 9th 2013

Several case studies highlighting the latest strategies and therapeutic agents available for patients with prostate cancer.

Herbert Irving Comprehensive Cancer Center Joins OncLive's Strategic Alliance Partnership

May 7th 2013

OncLive is pleased to announce that the Herbert Irving Comprehensive Cancer Center has joined its Strategic Alliance Partnership program. This program enables the Herbert Irving Comprehensive Cancer Center to promote its institution and faculty as leaders in oncology to a national audience of oncology professionals.

AUA Offers Evidence-Based Guide For Sequencing CRPC Therapies

May 6th 2013

The American Urological Association outlines clinical guidelines for sequencing castration-resistant prostate cancer therapies based on six "index patients" each with specific disease characteristics.

ODAC Turns Down Chemosaturation System

May 2nd 2013

Citing concerns about the safety profile of the device, ODAC unanimously recommended against the approval of the Melblez chemosaturation system for use with melphalan hydrochloride in the treatment of patients with ocular melanoma metastasized to the liver.

ODAC Votes Against Tivozanib in Renal Cell Carcinoma

May 2nd 2013

A single clinical trial was deemed insufficient to support approval of tivozanib for the treatment of patients with advanced renal cell carcinoma, according to a 13-1 vote by the FDA's Oncologic Drugs Advisory Committee.

Surveillance Following Orchiectomy Most Costly Option for Stage I Testicular Seminoma

May 2nd 2013

A cost analysis found that para-aortic radiotherapy, dogleg radiotherapy, and 1 cycle of carboplatin are cost-effective strategies for the management of stage I testicular seminoma post-orchiectomy compared with surveillance.

Breakthrough Designation Granted to Daratumumab for Double Refractory Multiple Myeloma

May 1st 2013

An investigational monoclonal antibody called daratumumab has received breakthrough therapy designation from the FDA for the treatment of patients with double refractory multiple myeloma.

PD-1 Targeted Antibody Lambrolizumab Receives FDA Breakthrough Designation

April 25th 2013

Lambrolizumab, an investigational antibody designed to target the programmed death-1 (PD-1) pathway in patients with melanoma, received a breakthrough therapy designation from the FDA after promising results from a small single-arm study.

Dr. Richard Silver Discusses the High Cost of Drugs in CML

April 24th 2013

Richard T. Silver, MD, from the New York Presbyterian-Weill Cornell Medical Center, comments on the cost of drugs to treat chronic myeloid leukemia.

Focusing on Clinical and Economic Outcomes-Not Guidelines: Is It Time for a New Direction in Oncology Care?

April 24th 2013

Interview With Andrew Pecora, MD, President, Regional Cancer Care Associates, Chief Innovations Officer and Vice President, Cancer Services, John Theurer Cancer Center at Hackensack University Medical Center, Editor-in-Chief, Oncology & Biotech News

April 2013 Biotech Focus: Tracking the Oncology Pipeline

April 19th 2013

The Biotech Focus series provides updates on advances in the oncology treatment pipeline. In each entry, summaries of ongoing research, breaking news, and FDA decisions relating to a variety of cancers are presented.

Emanuel Petricoin Describes Screening With Biomarkers

April 16th 2013

Emanuel F. Petricoin III, PhD, Co-Director, Center for Applied Proteomics & Molecular Medicine, Professor of Life Sciences, George Mason University, discusses disease screening with biomarkers.

Palbociclib Receives Breakthrough Designation for Treatment of Breast Cancer

April 10th 2013

The drug palbociclib (formerly known as PD-0332991) has received has received a "breakthrough therapy designation" from the FDA for the treatment of patients with breast cancer.

AACR Rally Protests Cuts to NIH Budget

April 8th 2013

Sign-toting scientists, students, patients, and caregivers gathered near the Carnegie Library in Washington, DC, to protest recent cuts to the budget of the National Institutes of Health, the largest funder of medical research in the world.

Ibrutinib Receives Additional Breakthrough Designation for CLL

April 8th 2013

After receiving breakthrough therapy designation from the FDA for the treatment of two B-cell malignancies earlier this year, ibrutinib has received an additional breakthrough designation.

Medicare Reimbursement Cuts Caused by Sequestration Begin to Take Effect

April 4th 2013

As a result of sequestration-related federal budget cuts, Medicare reimbursement has been reduced by 2% across the board, with the reduction affecting a number of services offered to cancer patients.

The Economic Value of Ipilimumab as a Second-Line Treatment in Patients With Advanced Melanoma

April 3rd 2013

Analysis of the cost-effectiveness of ipilimumab compared with best supportive care in previously treated patients with advanced (unresectable or metastatic) melanoma.

Conclusion: Optimal Side Effect Management in CRC

April 2nd 2013

Case Study: Treating Metastatic Colorectal Cancer

April 2nd 2013